scholarly journals Evaluation of primary breast cancers using dedicated breast PET and whole-body PET

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Deep K. Hathi ◽  
Wen Li ◽  
Youngho Seo ◽  
Robert R. Flavell ◽  
John Kornak ◽  
...  
Keyword(s):  
Treatment Response ◽  
Dynamic Range ◽  
Imaging Modality ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Whole Body ◽  
Metabolic Imaging ◽  
Primary Breast Tumor ◽  
Fdg Uptake ◽  
Dedicated Breast Pet

AbstractMetabolic imaging of the primary breast tumor with 18F-fluorodeoxyglucose ([18F]FDG) PET may assist in predicting treatment response in the neoadjuvant chemotherapy (NAC) setting. Dedicated breast PET (dbPET) is a high-resolution imaging modality with demonstrated ability in highlighting intratumoral heterogeneity and identifying small lesions in the breast volume. In this study, we characterized similarities and differences in the uptake of [18F]FDG in dbPET compared to whole-body PET (wbPET) in a cohort of ten patients with biopsy-confirmed, locally advanced breast cancer at the pre-treatment timepoint. Patients received bilateral dbPET and wbPET following administration of 186 MBq and 307 MBq [18F]FDG on separate days, respectively. [18F]FDG uptake measurements and 20 radiomic features based on morphology, tumor intensity, and texture were calculated and compared. There was a fivefold increase in SULpeak for dbPET (median difference (95% CI): 4.0 mL−1 (1.8–6.4 mL−1), p = 0.006). Additionally, spatial heterogeneity features showed statistically significant differences between dbPET and wbPET. The higher [18F]FDG uptake in dbPET highlighted the dynamic range of this breast-specific imaging modality. Combining with the higher spatial resolution, dbPET may be able to detect treatment response in the primary tumor during NAC, and future studies with larger cohorts are warranted.

18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography in Staging of Locally Advanced Breast Cancer

2004 ◽  
Vol 22 (7) ◽  
pp. 1253-1259 ◽  
Author(s):  
Jacobus J.M. van der Hoeven ◽  
Nanda C. Krak ◽  
Otto S. Hoekstra ◽  
Emile F.I. Comans ◽  
Robert P.A. Boom ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Distant Metastases ◽  
Emission Tomography ◽  
Whole Body ◽  
X Ray ◽  
Fdg Uptake ◽  
Positron Emission ◽  
Work Up

Purpose To prospectively evaluate the effect of adding whole-body 18F-2-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) to conventional screening for distant metastases in patients with locally advanced breast cancer (LABC). Patients and Methods All women with LABC referred for participation in the LABC Spinoza trial were considered eligible for this study. Patients were included if chest x-ray, bone scan, liver ultrasound, or computed tomography scan performed by the referring physician failed to reveal distant metastases. They underwent whole-body FDG PET scanning before therapy. Patients with subsequently proven distant metastases were switched to alternative forms of chemotherapy, hormonal therapy, or both. Results Among the 48 patients evaluated with PET, 14 had abnormal FDG uptake, and metastases were suspected in 12. After simple clinical evaluation (plain x-ray, history), 10 sites that were suggestive of abnormality remained. Further work-up revealed that four sites were metastases. Proven false positivity occurred in one patient with sarcoidosis. In the other five patients, the reason for abnormal FDG uptake (liver, lung, bone) remained unclear, and patients were treated as planned. Eleven months later, distant metastases were found in one patient at sites unrelated to the previous FDG uptake. Conclusion The addition of FDG PET to the standard work-up of patients with LABC may lead to the detection of unexpected distant metastases. This may contribute to a more realistic stratification between patients with true stage III breast cancer and those who are in fact suffering from stage IV disease. Abnormal PET findings should be confirmed to prevent patients from being denied appropriate treatment.

scholarly journals A Proposed Dedicated Breast PET Lexicon: Standardization of Description and Reporting of Radiotracer Uptake in the Breast

Diagnostics ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1267
Author(s):  
Kanae K. Miyake ◽  
Masako Kataoka ◽  
Takayoshi Ishimori ◽  
Yoshiaki Matsumoto ◽  
Masae Torii ◽  
...  
Keyword(s):  
Imaging Modality ◽  
Tumor Biology ◽  
Whole Body ◽  
Fdg Uptake ◽  
Dedicated Breast Pet ◽  
Radiotracer Uptake ◽  
Positron Emission ◽  
18F Fdg ◽  
Morphology Characterization

Dedicated breast positron emission tomography (dbPET) is a new diagnostic imaging modality recently used in clinical practice for the detection of breast cancer and the assessment of tumor biology. dbPET has higher spatial resolution than that of conventional whole body PET systems, allowing recognition of detailed morphological attributes of radiotracer accumulation within the breast. 18F-fluorodeoxyglucose (18F-FDG) accumulation in the breast may be due to benign or malignant entities, and recent studies suggest that morphology characterization of 18F-FDG uptake could aid in estimating the probability of malignancy. However, across the world, there are many descriptors of breast 18F-FDG uptake, limiting comparisons between studies. In this article, we propose a lexicon for breast radiotracer uptake to standardize description and reporting of image findings on dbPET, consisting of terms for image quality, radiotracer fibroglandular uptake, breast lesion uptake.

scholarly journals Multiparametric MRI - local staging of prostate cancer and beyond

2019 ◽  
Vol 53 (2) ◽  
pp. 159-170 ◽  
Author(s):  
Iztok Caglic ◽  
Viljem Kovac ◽  
Tristan Barrett
Keyword(s):  
Prostate Cancer ◽  
Imaging Modality ◽  
Imaging Techniques ◽  
Locally Advanced ◽  
Multiparametric Mri ◽  
Bone Involvement ◽  
Superior Performance ◽  
Whole Body ◽  
Clinical Prognosis ◽  
Local Staging

Abstract Background Accurate local staging is critical for treatment planning and prognosis in patients with prostate cancer (PCa). The primary aim is to differentiate between organ-confined and locally advanced disease with the latter carrying a worse clinical prognosis. Multiparametric MRI (mpMRI) is the imaging modality of choice for the local staging of PCa and has an incremental value in assessing pelvic nodal disease and bone involvement. It has shown superior performance compared to traditional staging based on clinical nomograms, and provides additional information on the site and extent of disease. MRI has a high specificity for diagnosing extracapsular extension (ECE), seminal vesicle invasion (SVI) and lymph node (LN) metastases, however, sensitivity remains poor. As a result, extended pelvic LN dissection remains the gold standard for assessing pelvic nodal involvement, and there has been recent progress in developing advanced imaging techniques for more distal staging. Conclusions T2W-weighted imaging is the cornerstone for local staging of PCa. Imaging at 3T and incorporating both diffusion weighted and dynamic contrast enhanced imaging can further increase accuracy. “Next generation” imaging including whole body MRI and PET-MRI imaging using prostate specific membrane antigen (68Ga-PSMA), has shown promising for assessment of LN and bone involvement as compared to the traditional work-up using bone scintigraphy and body CT.

scholarly journals FDG-PET-CT in the early response evaluation for primary systemic therapy of breast cancer

Open Medicine ◽  
2014 ◽  
Vol 9 (2) ◽  
pp. 306-312
Author(s):  
Tímea Tőkés ◽  
László Torgyík ◽  
Janina Kulka ◽  
Katalin Borka ◽  
Attila Szász ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systemic Therapy ◽  
Fdg Pet ◽  
Imaging Modality ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Early Response ◽  
Primary Systemic Therapy ◽  
Pet Ct ◽  
Fdg Pet Ct

AbstractPrimary systemic therapy (PST) is a standard treatment for patients with locally advanced breast cancer. We report one of our patients to demonstrate the optimal use of FDG-PET-CT in the routine clinical workup during PST, especially when clinicians face contradictory clinical and pathological findings, and to show the advantages of this imaging modality in the decision-making process about the initial treatment choice. By reviewing the literature we would also like to confirm that FDG-PET-CT is highly sensitive in the measurement of the early therapeutic response and the prediction of the complete pathological remission, as early as after the first cycle of chemotherapy is administered.

Sign in / Sign up

Export Citation Format

Share Document